Jacob Vorstman is associate professor of psychiatry at the University of Toronto and director of the Autism Research Unit at the Hospital for Sick Children in Canada. Initially, his research focused on the psychiatric and genetic aspects of the 22q11.2 deletion. After obtaining his Ph.D. in 2008, he broadened the scope from 22q11.2 deletion syndrome to the study of genotype-phenotype relations in neurodevelopmental conditions — in particular, autism, intellectual disability and schizophrenia. His ambition is to further insights into the genetic architecture underlying these conditions as well as to improve methods to measure the associated phenotypes.
Jacob Vorstman
Professor
The Hospital for Sick Children
From this contributor
A genetics-first clinic for catching developmental conditions early: Q&A with Jacob Vorstman
A new clinic is assessing children who have a genetic predisposition for autism and other neurodevelopmental conditions—sometimes before traits appear.
A genetics-first clinic for catching developmental conditions early: Q&A with Jacob Vorstman
How polygenic scores can improve predictions about autism, schizophrenia
Jacob Vorstman wants to help people who have rare mutations tied to autism, schizophrenia and other neurodevelopmental conditions set expectations about outcomes.
How polygenic scores can improve predictions about autism, schizophrenia
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.